You're contacting media contact of this press release

Title: C&R Research Strengthens Position as Korea’s Leading Global Clinical Trial Hub

Seoul, Korea South, 18th Nov 2025 - Established in 1997 as Korea’s first full-service Contract Research Organization (CRO), C&R Research has played a pioneering role in shaping the nation’s clinical research industry. With nearly 30 years of regulatory and operational expertise, the company has earned the trust of global pharmaceutical and biotech partners. In 2023, C&R Research expanded into the U.S. market with the launch of its subsidiary, C&R US, marking a significant step in its global growth strategy. Jinhak Kim, President of C&R US, presenting global clinical experience at 2025 BIO USA. Connecting the U.S. and Korea in Global Clinical TrialsNow in its second year, C&R US continues to expand its presence through trusted partnerships with U.S.-based pharmaceutical companies, biotechnology firms, and CROs.The company has successfully supported multiple Investigational New Drug (IND) applications across key therapeutic areas, including atopic dermatitis, solid tumors, biosimilars, and medical devices, while also providing Pre-IND meeting support to help clients design efficient early-stage development strategies.C&R Research: Gateway to Accelerated Global Market EntryKorea ranks among the world’s leading destinations for clinical research (6th globally, with Seoul ranked 2nd among cities), supported by advanced hospital infrastructure, high-quality medical standards, and strong patient recruitment capabilities.Based on internal benchmarking and cost comparisons, the country’s streamlined regulatory framework, featuring parallel IRB and IND review, enables faster study start-up, while overall clinical costs are estimated to be up to 40 - 50% lower than in the United States. Leveraging these advantages, C&R...

This press release is issued by King Newswire